Uro-PGx

Sale price $450.00 Regular price $500.00

Shipping calculated at checkout.

Pharmacogenomic Test for Drugs Related to Urological Disorders

This PGx test uses a simple cheek swab to test a combination of genes related to the metabolism of drugs used in the treatment of urological problems like incontinence and enlarged prostate.

If you are currently taking one of the following drugs, FDA recommends getting tested to determine if you have a gene mutation that could render a drug ineffective, cause unwanted side effects or result into a life-threatening event. Based on this information, your healthcare provider can suggest a different drug that can be safer and more effective. 

Private Pay

 

 

Buying this kit online is easy. We'll mail the kit to your home address with complete instructions immediately after the purchase. Once we receive your cheek swab, we'll sent the test results to your email ID in a password protected file within 5 business days.

 

 

Paid by Insurance:

 

 

PGx Tests are covered (once in a lifetime) by all major insurances including Medicare and Medicaid (if ordered by your provider). If you are currently taking one of these medications and have not performed a PGx test before, ask your healthcare provider is this test is right for you? You can download an order form here and take it to your provider. After filling it up completely, your healthcare provider's office will need to fax it to TopBlood at (512) 686-8972. A patient consent form that can be downloaded here is also required. The consent form can be separately emailed to us at admin@topbloodtest.com. Once we receive the documents, we'll mail you the kit to your home address for sample collection. Once we receive your cheek swab, we'll fax the test results to your healthcare provider within 5 business days.

DRUG

INDICATION

GENE

Darifenacin

Overreactive Bladder

CYP2D6

Fesoterodine

Incontinence

CYP2D6

Mirabegron

Overreactive Bladder

CYP2D6

Tamsulosin

Enlarged Prostate

CYP2D6

Tolterodine

Incontinence

CYP2D6

 

For further understanding, please refer to the United States FDA recommendations on Pharmacogenomic Biomarkers in Drug Labeling.